Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · IEX Real-Time Price · USD

1.750

0.00 (0.00%)

At close: May 1, 2024, 4:00 PM

1.780

+0.030 (1.71%)

After-hours: May 1, 2024, 7:43 PM EDT

Xeris Biopharma Holdings Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	259	325	181	365	241	190	355
Market Cap Growth	-	79.47%	-50.50%	51.64%	26.61%	-46.35%	-
Enterprise Value	416	481	257	351	194	173	274
PE Ratio	-5.21	-5.21	-1.91	-2.98	-2.64	-1.51	-5.90
PS Ratio	1.58	1.98	1.64	7.37	11.79	69.92	146.41
PB Ratio	-47.86	-47.86	4.00	3.84	7.14	13.18	4.70
P/FCF Ratio	-6.59	-6.59	-1.75	-3.78	-2.98	-1.80	-6.14
P/OCF Ratio	-6.90	-6.90	-1.76	-3.82	-2.99	-1.82	-6.30
EV/Sales Ratio	2.54	2.94	2.33	7.08	9.50	63.58	113.08
EV/EBITDA Ratio	-20.28	-20.28	-3.71	-3.09	-2.45	-1.47	-4.79
EV/EBIT Ratio	-13.05	-13.05	-3.13	-3.04	-2.41	-1.46	-4.76
EV/FCF Ratio	-9.77	-9.77	-2.48	-3.63	-2.40	-1.64	-4.74
Debt / Equity Ratio	-33.79	-33.79	4.38	0.92	2.58	4.04	0.42
Debt / EBITDA Ratio	-9.66	-9.66	-2.86	-0.77	-1.10	-0.49	-0.56
Debt / FCF Ratio	-4.65	-4.65	-1.92	-0.91	-1.08	-0.55	-0.55
Quick Ratio	1.17	1.17	2.08	1.52	4.99	2.94	11.35
Current Ratio	1.64	1.64	2.54	1.80	5.40	3.20	11.59
Asset Turnover	0.50	0.50	0.34	0.26	0.13	0.02	0.03
Interest Coverage	-1.39	-1.39	-5.81	-16.09	-7.56	-16.60	-22.61
Return on Equity (ROE)	-610.80%	-610.80%	-139.90%	-312.60%	-366.20%	-209.30%	-683.70%
Return on Assets (ROA)	-19.10%	-19.10%	-29.00%	-65.00%	-59.60%	-94.40%	-72.80%
Return on Capital (ROIC)	-19.79%	-19.79%	-33.69%	-62.82%	-69.17%	-168.24%	-55.31%
Earnings Yield	-24.00%	-19.18%	-52.34%	-33.59%	-37.82%	-65.99%	-16.94%
FCF Yield	-19.00%	-15.18%	-57.18%	-26.44%	-33.59%	-55.41%	-16.29%
Buyback Yield / Dilution	-1.51%	-1.51%	-71.62%	-85.32%	-63.32%	-116.75%	-493.92%
Total Shareholder Return	-1.51%	-1.51%	-71.62%	-85.32%	-63.32%	-116.75%	-493.92%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).